Research progress on the correlation between polymorphism of immunoregulatory gene and susceptibility to Graves' disease

doi:10.16352/j.issn.1001-6325.2023.03.495

Abstract

Abstract: Graves' disease(GD)is an organ-specific autoimmune disease with genetic background. The core pathogenesis of GD is immune factors, but genetic factors also play an important role in it. The susceptibility genes of GD are mainly divided into immunoregulatory gene and thyroid specific gene. The polymorphism of immunoregulatory gene may have some impact on the susceptibility of GD through various mechanisms, which may provide new ideas for the further study of the susceptibility genes and pathogenesis of GD.

Key words: Graves' disease, susceptibility gene, gene polymorphism, immunoregulatory gene

CLC Number:

R581.1

WANG Yujie, YANG Mengdi, HE Fengying, DING Yulu, SUN Linnan, ZHEN Donghu. Research progress on the correlation between polymorphism of immunoregulatory gene and susceptibility to Graves' disease[J]. Basic & Clinical Medicine, 2023, 43(3): 495-499.

References

[1]Dvornikova KA, Bystrova EY, Platonova ON, et al. Polymorphism of Toll-like receptor genesand autoimmune endocrine diseases[J]. Autoimmun Rev, 2020, 19:102496.doi:10.1016/j.autrev.2020.102496.
[2]Shehjar F, Dil A, Misgar RA, et al. A significant association of the CTLA4 gene variants with the risk of autoimmune Graves' disease in ethnic Kashmiri population[J]. Cell Immunol, 2020, 347:103995.doi:10.1016/j.cellimm.2019.103995.
[3]Hosseini A, Gharibi T, Marofi F, et al. CTLA-4: from mechanism to autoimmune therapy[J]. Inter Immunophacol, 2020, 80:106221.doi:10.1016/j.intimp.2020.106221.
[4]Sun W, Zhang X, Wu J, et al. Correlation of TSHR and CTLA-4 single nucleotide polymorphisms with Graves' disease[J]. Inter J Genomics, 2019, 2019:6982623.doi:10.1155/2019/6982623.
[5]葛绾宇, 孙卫华, 张晓梅, 等. 4p14区段和CTLA-4基因多态性与Graves病相关[J]. 基础医学与临床, 2016, 36:1246-1251.
[6]Huang F, He Q, Jiao X, et al. Meta-analysis of CTLA-4 +49 gene polymorphism and susceptibility to Graves' disease[J]. Crit Rev Eukaryot Gene Expr, 2020, 30:377-390.
[7]Chen X, Hu Z, Liu M, et al. Correlation between CTLA-4 and CD40 gene polymorphisms and their interaction in graves' disease in a Chinese Han population[J]. BMC Med Genet, 2018, 19:171.doi:10.1186/s12881-018-0665-y.
[8]Bufalo NE, Dos Santos RB, Rocha AG, et al. Polymorphisms of the genes CTLA4, PTPN22, CD40, and PPARG and their roles in Graves' disease: susceptibility and clinical features[J]. Endocrine, 2021, 71:104-112.
[9]Wawrusiewicz-Kurylonek N, Koper-Lenkiewicz OM, Gos＇cik J, et al. Association of PTPN22 polymorphism and its correlation with Graves' disease susceptibility in Polish adult population-A preliminary study[J]. Mol Genet Genomic Med, 2019, 7:e661.doi:10.1002/mgg3.661.
[10]Wu H, Wan S, Qu M, et al. The relationship between PTPN22 R620W polymorphisms and the susceptibility to autoimmune thyroid diseases: an updated meta-analysis[J]. Immunol Invest, 2022, 51:438-451.
[11]Wang XM, Tu JC. TNFSF15 is likely a susceptibility gene for systemic lupus erythematosus[J]. Gene, 2018, 670:106-113.
[12]Yang GL, Han Z, Xiong J, et al. Inhibition of intra-cranial hemangioma growth and hemorrhage by TNFSF15[J]. FASEB J, 2019, 33:10505-10514.
[13]Okamoto M, Watanabe M, Inoue N, et al. Gene polymorphisms of VEGF and VEGFR2 are associated with the severity of Hashimoto's disease and the intractability of Graves' disease, respectively[J]. Endocr J, 2020, 67:545-559.
[14]Abe I, Islam F, Lo CY, et al. VEGF-A/VEGF-B/VEGF-C expressions in non-hereditary, non-metastatic phaeochromocytoma[J]. Histol Histopathol, 2021, 36:645-652.
[15]Zhao H, Zhang Q. Signaling in TNFSF15-mediated suppression of VEGF production in endothelial cells[J]. Methods Mol Biol(Clifton, N.J.), 2021, 2248:1-18.
[16]钟霞, 赵家军, 戴晓华, 等. VEGF、IGF-Ⅰ与Graves病患者甲状腺内血管形成的关系[J]. 中华内分泌代谢杂志, 2006, 119-120.
[17]Zhang M, Liu S, Xu J, et al. TNFSF15 polymorphisms are associated with Graves' disease and Graves' ophthalmopathy in a Han Chinese population[J]. Curr Eye Res, 2020, 45:888-895.
[18]Fallahi P, Ferrari SM, Elia G, et al. Cytokines as targets of novel therapies for Graves' ophthalmopathy[J]. Front Endocrinol, 2021, 12:654473.doi:10.3389/fendo.2021.654473.
[19]Maklakova TP, Zorina VN, Yanysheva AV, et al. Immunoregulatory proteins and cytokines in the blood of patients with Graves' disease[J]. Probl Endokrinol, 2019, 65:4-9.
[20]Zhu Q, Su J, Wang X, et al. Serum concentrations of TNF-α and its soluble receptors in Graves' disease[J]. Endocr Connect, 2020, 9:736-746.
[21]Ferrari SM, Fallahi P, Elia G, et al. Novel therapies for thyroid autoimmune diseases: an update[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34:101366.doi:10.1016/j.beem.2019.101366.
[22]Boskovic O, Medenica S, Radojevic N, et al. Etanercept in the treatment of Graves' ophthalmopathy with primary hypothyroidism and rheumatoid arthritis[J]. Cent Eur J Immunol, 2019, 44:463-465.
[23]Hirai N, Watanabe M, Inoue N, et al. Association of IL6 gene methylation in peripheral blood cells with the development and prognosis of autoimmune thyroid diseases[J]. Autoimmunity, 2019, 52:251-255.
[24]Zhu P, Wu X, Zhou J, et al. Gene polymorphisms of pro-inflammatory cytokines may affect the risk of Graves' disease: a Meta-analysis[J]. J Endocrinol Invest, 2021, 44:311-319.